ACADIA Pharmaceuticals, Inc. (ACAD) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Apellis Pharmaceuticals, Inc.

Exelixis, Inc.

Alkermes Plc

Intra-Cellular Therapies, Inc.

ACADIA Pharmaceuticals, Inc.

Perrigo Co. Plc

Organon & Co.

Ionis Pharmaceuticals, Inc.

Catalent, Inc.

Insmed, Inc.

Karuna Therapeutics, Inc.

Why is ACADIA Pharmaceuticals, Inc. ?

Poor Management Efficiency with a low ROE of 5.98%

The company has been able to generate a Return on Equity (avg) of 5.98% signifying low profitability per unit of shareholders funds

The company has declared Positive results for the last 6 consecutive quarters

OPERATING CASH FLOW(Y) Highest at USD 187.91 MM
RAW MATERIAL COST(Y) Fallen by 0.34% (YoY)
NET PROFIT(9M) Higher at USD 189.39 MM

With ROE of 29.91%, it has a very attractive valuation with a 4.81 Price to Book Value

Over the past year, while the stock has generated a return of 47.46%, its profits have risen by 13484.8%

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating Performance

The stock has generated a return of 47.46% in the last 1 year, much higher than market (S&P 500) returns of 12.33%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to ACADIA Pharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is ACADIA Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

ACADIA Pharmaceuticals, Inc.

62.88%

1.28

50.05%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

20.98%

EBIT Growth (5y)

18.97%

EBIT to Interest (avg)

-91.06

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.88

Sales to Capital Employed (avg)

1.49

Tax Ratio

13.58%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

18.60%

ROE (avg)

5.98%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.81

EV to EBIT

34.05

EV to EBITDA

29.59

EV to Capital Employed

31.66

EV to Sales

3.02

PEG Ratio

Dividend Yield

ROCE (Latest)

92.98%

ROE (Latest)

29.91%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 187.91 MM

RAW MATERIAL COST(Y)

Fallen by 0.34% (YoY

NET PROFIT(9M)

Higher at USD 189.39 MM

CASH AND EQV(HY)

Highest at USD 1,443.57 MM

NET SALES(Q)

Highest at USD 264.57 MM

OPERATING PROFIT(Q)

Highest at USD 35.31 MM

-8What is not working for the Company

PRE-TAX PROFIT(Q)

At USD 40.21 MM has Fallen at -39.27%

NET PROFIT(Q)

At USD 26.67 MM has Fallen at -53.4%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.68 times

Here's what is working for ACADIA Pharmaceuticals, Inc.

Operating Cash Flow

Highest at USD 187.91 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Highest at USD 264.57 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD 35.31 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Cash and Eqv

Highest at USD 1,443.57 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Raw Material Cost

Fallen by 0.34% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for ACADIA Pharmaceuticals, Inc.

Pre-Tax Profit

At USD 40.21 MM has Fallen at -39.27%

over average net sales of the previous four periods of USD 66.21 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD 26.67 MM has Fallen at -53.4%

over average net sales of the previous four periods of USD 57.22 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Inventory Turnover Ratio

Lowest at 1.68 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio